Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus | Zendy

Kerry M. Empey | Zendy; R. Stokes Peebles | Zendy; Jay K. Kolls | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

Author(s) -

Kerry M. Empey,

R. Stokes Peebles,

Jay K. Kolls

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/651603

Subject(s) - palivizumab , medicine , ribavirin , intensive care medicine , virus , monoclonal antibody , disease , mechanism (biology) , immunology , virology , antibody , hepatitis c virus , philosophy , epistemology

Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable. During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens. This article reviews these obstacles and presents the novel development strategies used to overcome many of them. Also discussed are promising new antiviral treatment candidates and their associated mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacologic manipulation of the host response to RSV disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research